Pulse Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLSE research report →
Range $58 – $70
Price Chart
About the company
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software.
- CEO
- Paul Arthur LaViolette
- IPO
- 2016
- Employees
- 116
- HQ
- Miami, FL, US
Get TickerSpark's AI analysis on PLSE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $3.35B
- P/E
- -38.19
- PEG
- 7.48
- P/S
- 2256.19
- P/B
- 17.96
- EV/EBITDA
- -40.12
- Div Yield
- 0.00%
- Gross Margin
- 9.44%
- Op Margin
- -5821.08%
- Net Margin
- -5603.88%
- ROE
- -77.88%
- ROIC
- -45.79%
Latest fiscal year · YoY change
- Revenue
- $350.00K+0.0%
- Gross Profit
- $-1,260,000+0.0%
- Op Income
- $-76,939,000
- Net Income
- $-72,781,000-35.8%
- EPS
- $-1.08-17.4%
- OCF Growth
- -48.9%
- FCF Growth
- -49.3%
- 52W High
- $58.94
- 52W Low
- $12.70
- 50D MA
- $51.30
- 200D MA
- $33.97
- Beta
- 1.64
- RSI (14)
- 41
- Avg Volume
- 503.30K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Pulse Biosciences said it had a strong quarter, with Nano-Pulse AF fully enrolled ahead of schedule and a much stronger cash position to fund pre-commercial buildout.· November 5, 2026
- Nano-Pulse AF reached its enrollment target in early October, with 169 evaluable patients and 189 total patients, finishing about three months ahead of the original plan.
- Cash and marketable securities rose to $189.2 million at quarter-end, supported by more than $150 million of ATM net proceeds since May.
- Q3 revenue was $395,000, up $86,000 year over year, while GAAP net loss was $23.1 million and non-GAAP net loss was $17.5 million.
- Management emphasized pre-launch readiness: manufacturing scale-up, mapping-system integration, market access, segmentation, and other commercialization planning.
- The company reiterated multiple 2027 milestones, including final Nano-Pulse AF data in Q3 2027, CE Mark approval in Q4 2027, and a persistent AF IDE submission by year-end 2026.
Third-quarter revenue was $395,000, up $86,000 from the prior-year period. Cost of product revenue was $191,000, total GAAP costs and expenses were $24.7 million versus $20.5 million a year ago, and total non-GAAP costs and expenses were $19.1 million versus $14.6 million a year ago. GAAP net loss was $23.1 million compared with $19.4 million in the prior year period, and non-GAAP net loss was $17.5 million compared with $13.5 million. Cash and marketable securities were $189.2 million as of September 30, 2026, up from $101.6 million at June 30, 2026. Management said quarterly non-GAAP costs and expenses are expected to rise 15% to 25% above the Q2/Q3 average of about $20 million, mainly for EP catheter-related activities; it also reiterated approximately two years of cash runway and noted about $64 million of remaining ATM capacity.
Paul LaViolette framed the quarter as strong execution across clinical and financing priorities, highlighting that Nano-Pulse AF enrollment was completed in less than six months and well ahead of schedule. He spent much of the call on strategic positioning: manufacturing scale-up, commercial-readiness planning, mapping integration, and building a broader evidence base to support launch and potential partnerships. His tone was confident and expansive, stressing that nsPFA is differentiated from microsecond PFA and that the company is preparing for multiple growth paths across cardiac and other indications.
Jon Skinner focused on the financial buildout and burn profile. He said the company raised more than $150 million in net proceeds since May, including $95.8 million during the third quarter, and ended with $189.2 million in cash and marketable securities; cumulative ATM dilution in 2026 was less than 6%, and roughly $64 million of ATM capacity remained. He also noted third-quarter operating cash use of $15.3 million, lighter than Q2’s $18.7 million, and said spending should increase as the company moves into the persistent AF IDE, added clinical studies, manufacturing capabilities, and other pre-commercial work.
Analysts pressed management on launch readiness, reimbursement, mapping-system integration, hemolysis risk, and whether a side-by-side study versus microsecond PFA is needed. Management said it is already working on scale-up for both consoles and catheters, adding manufacturing and commercial competencies, and expanding integration beyond Abbott EnSite to other mapping systems. On hemolysis, Paul said the company used pre-procedure fluids in the IDE and that higher dosing can be mitigated with fluids, while declining to give interim data. On the comparative study, management said the goal is to validate the mechanistic differences of nsPFA, not simply to market a head-to-head commercial comparison.
The bull case from the call is that management believes the technology is already showing differentiated workflow and clinical performance, with rapid enrollment and strong physician enthusiasm backing that view. The company also now has a much larger cash cushion to fund regulatory work, manufacturing scale-up, and pre-launch investments through key milestones.
The main risks are that the company still has no commercial product clearance, and the pivotal AF data will not be available until Q3 2027, with CE Mark targeted for Q4 2027. Execution risk remains high around manufacturing scale-up, future clinical results, reimbursement dynamics, and whether the strong European feasibility results translate cleanly to the U.S. pivotal study and eventual commercialization.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 18.5%
- Shares Outstanding
- 73.55M
- Float Shares
- 13.57M
of shares held by institutions
112 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Price T Rowe Associates Inc | 2.79M | ▲ 2.04M |
| Blackrock, Inc. | 1.67M | ▲ 207.19K |
| Citadel Advisors LLC | 1.48M | ▲ 857.90K |
| Bank Of America Corp | 1.47M | ▲ 20.57K |
| Vanguard Group Inc | 1.12M | ▲ 5.05K |
| Vanguard Capital Management LLC | 937.95K | ▲ 149.31K |
| Balyasny Asset Management L.P. | 631.67K | ▼ 86.43K |
| State Street Corp | 547.97K | ▲ 18.35K |
| Geode Capital Management, LLC | 544.42K | ▲ 8.14K |
| Jpmorgan Chase & Co | 521.99K | ▲ 513.60K |
| Massachusetts Financial Services Co | 406.24K | ▼ 56.49K |
| Holocene Advisors, LP | 338.61K | ▲ 338.61K |
Held by 189 ETFs
Biggest fund positions in PLSE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 1, 26 | Teplitsky Liane Rae | buy | 1,001 |
| Aug 31, 26 | Teplitsky Liane Rae | buy | 1,024 |
| Aug 28, 26 | Teplitsky Liane Rae | buy | 1,034 |
| Aug 26, 26 | Teplitsky Liane Rae | buy | 1,036 |
| Aug 8, 26 | Teplitsky Liane Rae | other | 700,000 |
| Aug 8, 26 | Teplitsky Liane Rae | other | 200,000 |
| Apr 8, 26 | Teplitsky Liane Rae | other | 0 |
| Feb 3, 25 | Skinner Jon | other | 300,000 |
| Feb 3, 25 | Skinner Jon | other | 0 |
| Jun 11, 26 | Zanganeh Mahkam | other | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PLSE coverage
Recent articles, reports, and earnings notes.
No research on PLSE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PLSE report →Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Nov 20
Buy 3 Medical Device Stocks for a Stable Portfolio With Solid Upside
zacks.com · Nov 20
Pulse Biosciences to Present at Piper Sandler 38th Annual Healthcare Conference
businesswire.com · Nov 19
All You Need to Know About Pulse Biosciences (PLSE) Rating Upgrade to Buy
zacks.com · Nov 18
What Pulse Biosciences (PLSE) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting
businesswire.com · Nov 6
Pulse Biosciences, Inc. (PLSE) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results
businesswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.